BRAIN and Südzucker cooperate in the field of CO2 utilisation by microorganisms
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Alliance
2016-04-13 / 10:01
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
BRAIN and Südzucker cooperate in the field of CO2 utilisation by
microorganisms
Zwingenberg, April 13, 2016 - BRAIN AG (ISIN DE0005203947 / WKN 520394),
one of Europe's bio-economy leaders, expands its cooperation with Südzucker
AG in the field of microbial utilisation of carbon dioxide. The cooperation
with the largest producer of sugar in the European Union is co-financed by
the German Ministry of Education and Research (BMBF) as part of the
strategic alliance ZeroCarbFP. It aims at making the industrial by-product
CO2 available for the production of a multitude of economically interesting
intermediates by using microorganisms.
Based on very promising laboratory results during Phase 1 of the alliance,
the two partners have now applied for further funding with the BMBF in
order to scale up the process to a pilot facility at Südzucker's
CO2-emitting bioethanol plant in Zeitz during Phase 2. The goal is to
transform the CO2 generated during the production of bioethanol into a
material building block by using specific microorganisms, and ultimately to
reduce CO2 emissions. The intermediate products generated from CO2, such as
mono- and dicarboxylic acids, may then be utilised as specialty products in
the bioplastics industry, which so far has been dependent on fossil
resources.
"We are delighted to have reached the first milestones in our cooperation
using CO2 as a valuable resource," says Dr Jürgen Eck, CEO of BRAIN AG. "In
addition, we see the potential of using the technology, which we developed
in cooperation with our partner, in other CO2-emitting processes as well,
thus permitting us to make it available for wide-spread industrial use. The
microorganisms are undemanding and can easily adapt to different sources of
carbon dioxide."
In comparison to other processes, the two-stage process co-developed with
Südzucker for the utilisation of CO2 from bioethanol plants allows for high
carbon fixation rates as well as a variety of mono- and dicarboxylic acids
for the production of biopolymers.
For additional information please refer to the joint press release of BRAIN
AG and Südzucker AG at https://www.brain-biotech.de/en/press.
About BRAIN
BRAIN AG is one of Europe's technology leaders in the field of industrial
'white' biotechnology. Within strategic alliances, BRAIN AG has identified
and developed numerous innovative products and solutions for companies in
the chemical, pharmaceutical, cosmetic and food industries by harnessing
nature's untapped biodiversity. These active product components are
identified by BRAIN AG and contained in the company's "BioArchive", one of
the most comprehensive archives of its kind. Since its foundation in 1993,
BRAIN has entered into 102 strategic cooperations with nearly every
prominent company in the chemical industry. Cooperation partners include
BASF, Bayer Schering, Clariant, DSM, Evonik Degussa, Henkel, Nutrinova,
RWE, Sandoz, Südzucker and Symrise. The company currently employs around
120 highly skilled personnel.
www.brain-biotech.de
Contact:
B.R.A.I.N
Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
Tel.: +49-6251-9331-0
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de
www.brain-biotech.de
Disclaimer
This publication does not constitute an offer to sell, or the solicitation
of an offer to buy or subscribe for any securities. The public offer of
shares of B.R.A.I.N. Biotechnology Research And Information Network AG is
already concluded. This release is not for publication, release or
distribution in the United States of America, Canada, Australia or Japan.
This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that
could cause actual results, performance or events to differ materially from
those expressed or implied in such statements. There are numerous factors
which could influence the future performance by and future developments at
BRAIN AG and the BRAIN group of companies. Such factors include, but are
not limited to, changes in the general economic and competitive
environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations,
in particular with respect to tax laws and regulations, and other factors.
BRAIN AG does not undertake any obligation to update or revise any
forward-looking statements.
---------------------------------------------------------------------------
2016-04-13 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.de
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service